NCT03414229View on ClinicalTrials.gov

A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

January 23, 2018

Primary Completion Date

September 9, 2024

Study Completion Date

January 31, 2026

Conditions

Sarcoma

Interventions

DRUG

Epacadostat

100mg bid days 1-21

DRUG

Pembrolizumab

200mg/dose Day 1, Q 3 weeks

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Incyte Corporation

All Listed Sponsors

collaborator

Incyte Corporation

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

M.D. Anderson Cancer Center

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER